hotspot -WSS

hotspot

author：explore 2025-10-03 00:38:20 - browse：96376

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Startling documents reveal new facets of Sacklers' opioid empire

entertainment

WSS

Childbirth

David Sabatini, ex

Focused ultrasound for uterine fibroids: an uphill battle

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Lab trade group sues FDA to halt regulation of lab

explore

hotspot

entertainment

Dobbs anniversary: the lost opportunity of abortion as health care

Akili, maker of video game for ADHD, to be acquired for 34 million

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

Trump demands the U.S. pay no more for drugs than other countries … again

A new initiative will help leaders fight the next pandemic

After affirmative action ruling, medical educators look to 'holistic review'

Fight over Supreme Court dialysis ruling puts kidney patients at risk

New air purifier tech could be key to improving indoor air quality

Stigma and the return of syphilis

hotspot

Anthony Fauci pushes back on GOP claims during Covid hearing

Take antibiotics after sex, CDC recommends for certain risk groups

An outdated Medicare rule harms dementia patients with anxiety

The most pressing bird flu mysteries scientists want answered

Congress needs to close a vaccine

How CO2 helps viruses stay alive longer in the air

hotspot

focus

entertainment

focus